Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

ABSTRACT: The use of immunomodulatory and immunosuppressive therapies in multiple sclerosis (MS) has allowed practitioners to regulate MS disease activity, with the caveat that these potent medications may render patients susceptible to opportunistic infections. The approval of fingolimod presented the first oral option for relapsing MS. Since 2015, postmarketing safety data have documented several published cases of cryptococcal meningitis and disseminated cryptococcosis associated with fingolimod use. However, surveillance mechanisms for opportunistic infections and management of active demyelinating disease with ongoing infection have not been adequately addressed. We present a case of isolated pulmonary cryptococcosis with the use of fingolimod to highlight the hurdles in balancing efficacious disease-modifying therapies for MS while treating an opportunistic infection associated with that therapy.

SUBMITTER: Samudralwar RD 

PROVIDER: S-EPMC6928584 | biostudies-literature | 2019 Nov-Dec

REPOSITORIES: biostudies-literature